H.R. 5850 explained · 118th Congress · Not enacted (118th Congress ended)
To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.
Introduced: 2023-09-29
Latest action (2023-10-06): Referred to the Subcommittee on Health.
What H.R. 5850 does, in plain terms
The Congressional Research Service has not published a summary of H.R. 5850 yet. Its official title: “To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.”.
Constitution Index
“VFA Constitution grade”
Not graded yet
H.R. 5850 has not been graded yet. New measures with an official summary are graded daily under the published rubric.
What should pass
“VFA SI Solution”
No solution yet
A sourced SI draft appears here once it passes automated checks (Constitution citation, source verification, independent SI critic). How publication works.
For journalists and bloggers
“Embed this grade”
Free to use with the link back. The badge and card update when the grade changes. Embed terms →
